Literature DB >> 32809268

The association of standard Kt/V and surface area-normalized standard Kt/V with clinical outcomes in hemodialysis patients.

Pattharawin Pattharanitima1,2, Kinsuk Chauhan1, Osama El Shamy1, Kumardeep Chaudhary3, Shuchita Sharma1, Steven G Coca1, Girish N Nadkarni1,3, Jaime Uribarri1, Lili Chan1.   

Abstract

INTRODUCTION: A previous study demonstrated that the surface area-normalized standard Kt/V (SAstdKt/V) was better associated with mortality than standard Kt/V (stdKt/V). This study investigates the association of SAstdKt/V and stdKt/V with mortality, anemia, and hypoalbuminemia in a larger patient cohort with a longer follow-up period.
METHODS: We included adult patients on thrice-weekly hemodialysis in the USRDS database and excluded amputated patients. StdKt/V and SAstdKt/V were calculated from the available single-pool Kt/V. Patients were categorized into five groups according to their stdKt/V and SAstdKt/V: <2.00, 2.00-2.19, 2.20-2.39, 2.40-2.59, and ≥2.60. Hazard ratios (HR) and odds ratios (OR) were calculated using Cox and logistic regression analysis respectively.
FINDINGS: There were 507,656 patients included in the analysis. The patients had a median age of 65.5 years with a median follow-up period of 2 years. Thirty-four percent died during follow-up. HRs for mortality progressively decreased as SAstdKt/V increased in both unadjusted and adjusted models. Unlike SAstdKt/V, HRs were the lowest in the categories with stdKt/V of 2.40-2.59 and they increased in the higher stdKt/V category. The adjusted HR for SAstdKt/V vs. stdKt/V were 0.68 vs. 0.62 in the category of 2.40-2.59, and 0.63 vs. 0.73 in the category of ≥2.60. The adjusted ORs for anemia progressively decreased as SAstdKt/V increased, whereas ORs decreased to the lowest in stdKt/V category 2.40-2.59 and increased in the ≥2.60 category. The adjusted ORs for hypoalbuminemia progressively decreased as SAstdKt/V and stdKt/V increased which were both 0.45 in 2.40-2.59 category and decreased to 0.29 and 0.42 in the ≥2.60 category. DISCUSSION: SAstdKt/V is better associated with mortality, anemia, and hypoalbuminemia than stdKt/V. SAstdKt/V is a better parameter in defining hemodialysis dosing which can be calculated by an available online tool. Further studies to determine the optimal SAstdKt/V dose required to achieve improved clinical outcomes with better cost-effectiveness are needed.
© 2020 International Society for Hemodialysis.

Entities:  

Keywords:  Adequacy of dialysis; anemia; nutrition; survival

Mesh:

Substances:

Year:  2020        PMID: 32809268      PMCID: PMC8006157          DOI: 10.1111/hdi.12865

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.543


  36 in total

Review 1.  KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update.

Authors: 
Journal:  Am J Kidney Dis       Date:  2015-11       Impact factor: 8.860

2.  Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients.

Authors:  Yoshitsugu Obi; Connie M Rhee; Anna T Mathew; Gaurang Shah; Elani Streja; Steven M Brunelli; Csaba P Kovesdy; Rajnish Mehrotra; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2016-05-11       Impact factor: 10.121

3.  Body size, dose of hemodialysis, and mortality.

Authors:  R A Wolfe; V B Ashby; J T Daugirdas; L Y Agodoa; C A Jones; F K Port
Journal:  Am J Kidney Dis       Date:  2000-01       Impact factor: 8.860

4.  Dialysis dose scaled to body surface area and size-adjusted, sex-specific patient mortality.

Authors:  Sylvia Paz B Ramirez; Alissa Kapke; Friedrich K Port; Robert A Wolfe; Rajiv Saran; Jeffrey Pearson; Richard A Hirth; Joseph M Messana; John T Daugirdas
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-13       Impact factor: 8.237

5.  Scaling Hemodialysis Target Dose to Reflect Body Surface Area, Metabolic Activity, and Protein Catabolic Rate: A Prospective, Cross-sectional Study.

Authors:  Sivakumar Sridharan; Enric Vilar; Andrew Davenport; Neil Ashman; Michael Almond; Anindya Banerjee; Justin Roberts; Ken Farrington
Journal:  Am J Kidney Dis       Date:  2016-09-20       Impact factor: 8.860

6.  Dialysis adequacy and nutritional status of hemodialysis patients.

Authors:  Fernanda Teixeira Nunes; Gianine de Campos; Sandra M Xavier de Paula; Vânia A Leandro Merhi; Kátia C Portero-McLellan; Denise G da Motta; Maria R M de Oliveira
Journal:  Hemodial Int       Date:  2008-01       Impact factor: 1.812

7.  Effect of dialysis dose and membrane flux in maintenance hemodialysis.

Authors:  Garabed Eknoyan; Gerald J Beck; Alfred K Cheung; John T Daugirdas; Tom Greene; John W Kusek; Michael Allon; James Bailey; James A Delmez; Thomas A Depner; Johanna T Dwyer; Andrew S Levey; Nathan W Levin; Edgar Milford; Daniel B Ornt; Michael V Rocco; Gerald Schulman; Steve J Schwab; Brendan P Teehan; Robert Toto
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

8.  The impact of visceral mass on survival in chronic hemodialysis patients.

Authors:  P Kotanko; N W Levin
Journal:  Int J Artif Organs       Date:  2007-11       Impact factor: 1.595

9.  The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.

Authors:  O Ifudu; J Feldman; E A Friedman
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

10.  Surface-area-normalized Kt/V: a method of rescaling dialysis dose to body surface area-implications for different-size patients by gender.

Authors:  John T Daugirdas; Thomas A Depner; Tom Greene; Martin K Kuhlmann; Nathan W Levin; Glenn M Chertow; Michael V Rocco
Journal:  Semin Dial       Date:  2008 Sep-Oct       Impact factor: 3.455

View more
  1 in total

1.  Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment.

Authors:  Ji Yong Jung; Kyung Don Yoo; Eunjeong Kang; Hee Gyung Kang; Su Hyun Kim; Hyoungnae Kim; Hyo Jin Kim; Tae-Jin Park; Sang Heon Suh; Jong Cheol Jeong; Ji-Young Choi; Young-Hwan Hwang; Miyoung Choi; Yae Lim Kim; Kook-Hwan Oh
Journal:  Kidney Res Clin Pract       Date:  2021-12-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.